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Abstract
Background and Aims—Opioid-related overdose is increasingly linked to pregnancy-
associated deaths, but factors associated with postpartum overdose are unknown. We aimed to 
estimate the strength of the association between maternal and infant characteristics and postpartum 
opioid-related overdose.
Design—Retrospective cohort study using a linked, population-level dataset.
Setting—Massachusetts, United States.
Participants—Women who delivered one or more live births from 2012–2014 (n=174,517).
Measurements—The primary outcome was opioid-related overdose in the postpartum year. We 
used multivariable logistic regression to explore the independent associations of maternal 
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(demographics, substance use, pregnancy) and infant (gestational age, birthweight, neonatal 
abstinence syndrome (NAS)) characteristics with postpartum opioid overdose. Findings were 
stratified by maternal opioid use disorder (OUD) diagnosis.
Findings—There were 189 deliveries to women who experienced ≥1 opioid overdose in the first 
year postpartum (11/10,000 deliveries). Among women with postpartum opioid overdose, 46.6% 
had an OUD diagnosis within twelve months before delivery. In our adjusted model, maternal 
diagnosis of OUD (aOR 3.61, 95% CI 1.73–7.51) and prior non-fatal overdose (aOR 2.40, 95% CI 
1.11–5.17) were most strongly associated with postpartum overdose. After stratifying by OUD 
status, infant diagnosis of NAS (OUD+ aOR 2.03, 95% CI 1.26–3.27; OUD- aOR 2.79, 95% CI 
1.12–6.93), and high unscheduled healthcare utilization (OUD+ aOR 2.27, 95% CI 1.38–3.73; 
OUD- aOR 2.11, 95% CI 1.24–3.58) were positively associated with postpartum overdose in both 
groups.
Conclusion—Among women who delivered live infants in Massachusetts, USA between 2012 
and 2014, maternal diagnosis of OUD, prior non-fatal overdose, infant diagnosis of NAS, and high 
unscheduled health care utilization appeared to be positively associated with postpartum opioid 
overdose. However, over half of postpartum overdoses in that period were to women without a 
diagnosis of OUD. Engagement in methadone or buprenorphine treatment in the month prior to 
delivery was not sufficient to reduce the odds of postpartum overdose.
Keywords
Pregnancy; postpartum; opioid use disorder; overdose; women; maternal; neonatal abstinence 
syndrome; non-fatal
Introduction
In the United States, opioid-related overdose events are increasingly implicated in 
pregnancy-associated deaths, defined as deaths occurring during or within a year of the end 
of pregnancy, contributing to 11 to 25% of deaths in several states.1–6 The majority of the 
reported deaths occur later in the postpartum period; in Massachusetts, over 90% of 
substance-use related pregnancy-associated deaths occurred after six weeks postpartum, 
compared with 60% of all other pregnancy-associated deaths.1–5 In Massachusetts, the seven 
to twelve months following delivery were found to be a period of increased risk of both fatal 
and non-fatal opioid overdose events (12.3/100,00 person-days) compared with the trimester 
just prior to delivery (3.3/100,00 person-days).7
The postpartum period is a vulnerable period where overdose can pose significant risks to 
maternal and child health and well-being. This time can be particularly challenging for 
mothers with opioid use disorder (OUD) given high rates of postpartum depression, 
fragmented transitions of care from prenatal to postpartum providers, lapses in insurance 
following delivery, physiologic changes impacting medication dose for treatment of OUD, 
and the shame and stigma experienced by women secondary to neonatal opioid withdrawal 
or loss of child custody.8–13
Overdose risk factors in the general population have been well described, including prior 
non-fatal overdose, greater severity of opioid use disorder, receipt of prescription opioids, 
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recent incarceration, depression, female gender, and housing instability.14–22 Yet unique risk 
factors for overdose among postpartum women in the year following delivery have not been 
specifically examined. The purpose of this study was to identify the extent to which maternal 
and infant characteristics identifiable at time of delivery were associated with opioid-related 
fatal and non-fatal overdose in the first postpartum year utilizing a linked-statewide 
population-level dataset in Massachusetts. We hypothesized that in addition to the factors 
previously described in the general population, inadequate prenatal care and preterm 
delivery would be associated with opioid-related overdose in the postpartum period. 
Additionally, among women who experienced postpartum overdose, we aimed to compare 
characteristics by OUD diagnosis, an important benchmark in identification of at-risk 
women during pregnancy.
Methods
Design
We performed a retrospective cohort study utilizing a statewide linked-dataset, called the 
Public Health Data Warehouse, previously described as the Chapter 55 database. This 
dataset was established as part of a Massachusetts (MA) legislative mandate and is overseen 
by the Massachusetts Department of Public Health (MDPH).23–25 Linkage across several 
state data sets from 2011–2015, including the All Payer Claims Database (APCD), Vital 
Records (birth and death certificates), Bureau of Substance Addiction Services (BSAS) 
licensed substance use disorder treatment data, the Center for Health Information and 
Analysis Case Mix records (inpatient hospitalization, observation encounters, and 
emergency department discharges), the Prescription Monitoring Program (PMP), MA 
Ambulance Trip Record Information System, and state Medicaid (MassHealth), among 
others, was performed by the MDPH to allow further exploration of factors that influence 
opioid overdoses. A full description of the datasets linked, data structure, and linkage rates 
across datasets has been described previously.26
Participants
Our cohort included all MA residents who delivered a live birth in MA and a documented 
gestational age ≥ 20 weeks, identified using birth certificates. Birth certificate linkage rates 
for our study period were 91.7%. Fetal death records were excluded. Our study cohort was 
limited to deliveries that occurred between January 2012 and September 2014, to allow for a 
full year of available data before and after each delivery. The study population included birth 
of both singleton and multiples (treated as a single delivery episode), as well as multiple 
deliveries to the same woman during the study period.
Measures
Our primary outcome of interest was any fatal or nonfatal opioid-related overdose during the 
365 days following delivery. Opioid-related overdose events were defined by identification 
of any of the following: (1) A discharge from an inpatient unit, observation unit, or an 
emergency department encounter with an indication of opioid overdose based on 
International Classification of Disease (ICD) Ninth Edition diagnosis codes for opioid 
poisoning (Supplementary Table 1); (2) An ambulance encounter with an indication of 
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opioid overdose based on an algorithm created by MPDH and the Centers for Disease 
Control and Prevention (available only from 2013–2015); or (3) A death certificate 
indicating opioid overdose as cause of death.
Maternal characteristics extracted from the birth certificate include age at time of delivery, 
race/ethnicity, highest educational level, marital status, and the adequacy of prenatal care 
utilization index.27 Enrollment in MassHealth (Medicaid) during the month of delivery was 
identified from the MassHealth insurance database. Additional characteristics were defined 
dichotomously based on any evidence in the 12 months before delivery, inclusive of month 
of delivery – homelessness, defined as an active casefile in the MA Department of Housing 
and Community Development (DHCD) dataset; incarceration, defined as release from 
incarceration in a prison or a jail in MA; and anxiety and depression, defined by APCD and 
Case Mix data. Finally, high utilization of unscheduled care, defined as three or more 
emergency department and/or obstetric triage visits in the 12 months before delivery, 
exclusive of the month of delivery based on Case Mix data.
Maternal OUD in the year prior to delivery was defined as an ICD-9 or ICD-10 code for 
opioid use disorder (Supplementary Table 1) in either APCD claims or Case Mix records. 
Women were defined as enrolled in an opioid treatment program if they had any evidence of 
enrollment in a state-funded program in the 12 months before delivery from BSAS records, 
which includes acute treatment services, crisis stabilization, residential, and intensive 
outpatient programs. Women were defined as receiving medication for OUD (MOUD) in the 
12 months before delivery and the month of delivery if they had a claim for methadone 
maintenance treatment (Supplementary Table 1), record of methadone treatment from 
BSAS, or had filled a prescription for buprenorphine or buprenorphine/naloxone. Non-fatal 
overdose in the year prior to delivery was defined as a claim or ambulance record for opioid 
overdose in the 365 days before delivery not linked to a death record. Finally, an opioid 
prescription filled in the 3 months prior to delivery, excluding buprenorphine, was 
determined from PMP data. Prescriptions in the month of delivery were excluded to avoid 
opioid prescriptions for postpartum pain control.
Mothers who delivered infants with neonatal withdrawal symptoms were identified by infant 
diagnosis claim of neonatal abstinence syndrome (NAS) (Supplementary Table 1). 
Gestational age, birthweight, delivery type, and receipt of breastmilk prior to discharge were 
identified from birth certificate data. To account for the collinearity between gestational age 
and birthweight, infants were described as preterm/low birthweight if they were born before 
37 weeks and/or weighed less than 2,500 grams. In order to have a single value for each 
delivery, infant characteristics were combined for multiple gestations (e.g., if one twin was 
diagnosed with NAS, the delivery was coded as NAS positive).
Analyses
We used descriptive statistics, including counts, percentages, and rates per 10,000 live births 
to compare the characteristics of women with postpartum overdose to women who delivered 
a live birth in Massachusetts but had no documented postpartum overdose for each covariate. 
We used generalized estimating equations logistic regression with an unstructured 
correlation structure to account for multiple deliveries to the same woman throughout the 
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study period. We developed three models: an unadjusted model, a model which controlled 
for maternal diagnosis of OUD, and a multivariable model that evaluated the association of 
all a priori maternal and infant covariates described earlier and postpartum overdose. 
Multivariable models were examined for potential collinearity by calculating variance 
inflation factors and condition indices. To examine the effect of a prior diagnosis of OUD, 
we assessed potential interactions between OUD diagnosis and each covariate in our 
multivariate models. Significant interactions were identified, so the final model was 
stratified by prior OUD diagnosis. All analyses were performed in SAS Studio version 3.6 
(Cary, NC). The Partners Institutional Review Board deemed this study exempt as non-
human subjects research.
Results
We identified 179,407 deliveries resulting in a live birth in Massachusetts during our study 
period. We excluded 4,890 (2.7%) deliveries that were missing maternal or infant covariates, 
leaving 174,517 deliveries (170,678 singleton and 3,839 multiples) in our final cohort 
among 164,765 unique women. There were 189 deliveries (all among unique women) with 
at least one postpartum opioid overdose in the year following delivery, affecting 
approximately 11/10,000 deliveries. Ninety-three percent of initial overdose events (176) 
were non-fatal and 58% (109) occurred in the 7–12 months following delivery (Figure 1).
Descriptive statistics for women in the study population are presented in Table 1. Women 
who had an overdose in the year following delivery were significantly more likely to be 
younger than age 25, white/non-Hispanic, less educated, unmarried, receiving public 
insurance at delivery, and have less than adequate prenatal care, when compared to all 
women in MA who delivered a live birth. In terms of opioid use and treatment in the year 
prior to delivery, women who had a postpartum overdose were significantly more likely to: 
have a diagnosis of OUD, enroll in a treatment program for an opioid problem, receive 
MOUD during the month of delivery, and fill an opioid prescription (excluding 
buprenorphine) in the three months prior to delivery. With respect to psychosocial history in 
the year before delivery, women with an overdose were significantly more likely to have a 
diagnosis of depression and anxiety, high unscheduled healthcare utilization, a history of 
incarceration, and evidence of homelessness. Finally, deliveries among women with a 
postpartum overdose were more likely to result in a preterm or low birthweight infant, 
diagnosis of NAS, and less initiation of breastfeeding.
We compared the characteristics of the deliveries of women who had an overdose who had 
evidence of OUD in the year before delivery (n=88) with those who did not have evidence of 
OUD (n=101) in Table 2. Women without prior evidence of OUD but who experienced a 
postpartum overdose were more likely to have adequate prenatal care and breastfeed their 
infant compared with women with a prior OUD diagnosis. Additionally, this group was less 
likely to have high unscheduled healthcare utilization and less likely to have a prior 
diagnosis of anxiety or depression, compared with deliveries to women with a prior OUD 
diagnosis.
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Our unadjusted model (Model 1) identified that diagnosis of OUD and opioid-related 
variables were most highly associated with a postpartum overdose. After adjusting for OUD 
status (Model 2) and all other covariates (Model 3) we found a significant reduction in the 
magnitude of the adjusted odds ratios (Supplementary Table 2). We identified evidence of a 
significant interaction between OUD diagnosis and the association between multiple 
covariates and postpartum overdose in our adjusted model. These findings led us to present 
our final model stratified by OUD diagnosis (Figure 2).
In the OUD positive group, infant NAS diagnosis, prior overdose in last 12 months, high ED 
utilization, and maternal anxiety were associated with postpartum overdose. In the OUD 
negative group, in addition to infant NAS diagnosis and higher ED utilization, we found that 
marital status, public insurance, preterm/low birthweight, C-section delivery, opioid 
treatment program involvement, opioid prescribing, and incarceration status were positively 
associated with postpartum overdose (Figure 2). For three covariates, marital status, 
enrollment in Medicaid, and opioid prescription three months before delivery, the direction 
of the adjusted odds ratio differed by OUD status, but they were not statistically significant 
in the final models. In both models, MOUD during the month of delivery was not 
statistically significantly associated with postpartum overdose.
Discussion
In a population-level cohort of more than 174,000 deliveries resulting in live births between 
2012–2014 in Massachusetts using a linked administrative dataset, postpartum overdose 
occurred at a rate of 11/10,000 deliveries. In our cohort, less than half of women with a 
postpartum overdose had a documented OUD diagnosis in the year prior to or during their 
delivery hospitalization, and maternal and infant characteristics associated with overdose 
differed by OUD status. In our final stratified models, factors significantly associated with 
postpartum overdose in both groups included infant diagnosis of NAS and high unscheduled 
healthcare utilization. For women in the OUD negative group, additional characteristics 
positively associated with postpartum overdose included public insurance, being unmarried, 
enrollment in a public opioid treatment program, preterm/low birth weight, cesarean 
delivery, and history of incarceration; conversely, older age and non-white race were 
associated with decreased odds of postpartum overdose.
We found that postpartum overdose is an uncommon event that occurs at a lower rate than 
overdose in the general population in Massachusetts (31/10,000 in 2015).25 While this rate 
was lower than reported national rates of other conditions affecting postpartum women in 
the United States such as depression (impacting 9–20% of all deliveries)28 or obstetrical 
complications requiring readmission (1–2% of all deliveries),29 we found the postpartum 
opioid-related overdose rate was similar to that of postpartum psychosis (0.1–0.5% of 
deliveries).28,30 Given postpartum overdose can result in significant morbidity and mortality 
for women and the prevalence of OUD in pregnancy continues to rise,31 identifying women 
at risk of overdose is important to offer harm reduction services such as naloxone 
distribution and provide addiction treatment.32,33
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Similar to prior studies, we found that a known history of an OUD and prior overdose were 
substantially associated with increased odds of postpartum overdose.15–19,34 Unique to 
postpartum women, we identified that an infant diagnosis of NAS at delivery and 
preterm/low birthweight at delivery were associated with a greater likelihood of postpartum 
overdose. For infant NAS diagnosis, we hypothesize that this association is most likely a 
proxy for maternal evidence of opioid use or recent opioid prescribing (70% of cases of 
NAS were to women with evidence of OUD). However, the shame and stigma women 
experience from watching their infant display withdrawal symptoms, grief from loss of 
parental custody, and stresses of caring for a potentially fussier baby could also contribute to 
this positive association. There remains great heterogeneity in the way providers classify 
opioid-exposed infants as having a diagnosis of NAS.35 Based on NAS claims diagnoses 
alone, we were unable to determine if an infant required pharmacologic treatment or not, 
and if differences in overdose exist by infant treatment status. Preterm or low birthweight 
infants may have special health care needs that increase the burden on caretakers in the year 
postpartum. Additionally, higher unscheduled health care utilization, but not inadequate 
prenatal care receipt, was associated with postpartum overdose. A qualitative study of low-
income pregnant women with high unscheduled care found utilization may be driven by 
experiences of illness insufficiently addressed by outpatient prenatal care.36 The experience 
of women having unmet health needs may portend future postpartum overdose risk, 
regardless of whether a diagnosis of OUD is identified at delivery.
In our stratified analysis among women with an OUD diagnosis, we found that a diagnosis 
of anxiety, but not depression in the year before delivery was significantly associated with 
postpartum overdose. In the OUD negative group, we found a similar but not statistically 
significant association between prior mental health diagnosis and postpartum overdose, 
likely due to insufficient power to detect an association. A history of psychopathology 
during pregnancy has been previously shown to be strongly associated with postpartum 
depression, which could contribute to postpartum relapse and overdose.8,37
Notably, there was no independent association between receiving MOUD the month of 
delivery and adjusted odds of postpartum overdose. This suggests that engagement in 
treatment with methadone or buprenorphine at time of delivery is not sufficient to reduce the 
odds of postpartum overdose. While our study design focused on factors identifiable at 
delivery, research has shown that discontinuation of MOUD increases overdose risk in the 
general population.33,38 Pregnancy represents a time where many women newly engage in 
treatment and receive MOUD, and the exploration of factors contributing to postpartum 
disengagement from treatment is an underexplored area for future research. For example, 
research exploring how caretaking responsibilities may interfere with the ability to engage in 
treatment and recovery supports, particularly as few treatment centers nationally have 
gender-specific and child care supports for women and their families.39
Finally, there has been an increasing body of literature examining opioid prescribing in 
women after delivery, as prescribing is routine after cesarean delivery40 but also common 
after vaginal delivery.41 In our stratified analysis among women without a diagnosis of 
OUD, we found a statistically significant association between cesarean delivery and 
postpartum overdose, which could be a proxy for postpartum opioid prescribing. However, a 
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recent analysis by Ladha and colleagues assessed overdose risk for 90 days following 
several common surgical procedures, and found post-cesarean delivery had one of the lowest 
odds of overdose among 22 surgical procedures studied.42 Future research examining 
specific postpartum prescribing patterns and overdose risk is warranted.
Compared with our prior work that restricted analyses to individuals with an OUD diagnosis 
in the year prior to delivery,7 this analysis included all live births in MA. Our study was 
designed to look at maternal and infant factors identifiable at time of delivery associated 
with postpartum overdose, to help identify individuals who may be at higher risk in the 
postpartum period, and thus be able to offer more intensive services and resources tailored to 
this population. While we found that OUD diagnosis was strongly associated with increased 
odds of postpartum overdose, over half the deliveries with a postpartum overdose were to 
women with no documented OUD diagnosis in the year prior to and including month of 
delivery. We hypothesize several explanations for this finding. First, women with an existing 
OUD may not have received prenatal substance use screening, or disclosed their substance 
use history fully during pregnancy for fear of losing custody of their child or stigma 
surrounding substance use disorder during pregnancy, and thus were not identified prior to 
delivery. Second, given our reliance on administrative rather than clinical data, women with 
OUD may not have been properly characterized/documented with a diagnosis code of OUD 
despite being known to have one, as prior work showed that OUD is underdocumented in 
claims data in Massachusetts.43 Third, women may have developed a new OUD or newly 
used opioids resulting in an overdose following delivery but did not have OUD prior to 
delivery. Finally, not all women who overdose meet criteria for OUD, particularly as 
overdose becomes more frequent due to contamination of fentanyl into the opioid and non-
opioid drug supply.15
Our subgroup analysis comparing those with a postpartum overdose by OUD status showed 
that these two groups of women had important differences in their characteristics. Those 
without a diagnosis claim for OUD had more adequate prenatal care engagement, less 
psychiatric comorbidity, less unscheduled health care utilization, higher rates of 
breastfeeding, and were less likely to deliver an infant with NAS, suggesting either less in-
utero opioid exposure during pregnancy or a lack of appropriate prenatal identification rather 
than absence of diagnosis due to lack of access to care. For this group of women, identifying 
ways in the postpartum period to have increased contact for screening for substance use 
disorder is important, particularly given 25–35% of all women do not attend their 
postpartum visit.44 Pediatric providers who have frequent visits with families in the first year 
following delivery could play an important role in screening for OUD and identifying risk 
factors among families including postpartum depression, isolation, and limited supports in 
caring for a new baby.45
Our study has several important limitations. First, our observational cohort using 
administrative data is subject to both selection bias and misclassification bias. We attempted 
to minimize this risk by removing deliveries with an implausible gestational age and 
controlling for maternal demographics in our final adjusted model. Second, as overdose was 
a rare event, we may not have had enough power in our model to show all factors associated 
with postpartum overdose, such as homelessness and depression. Third, our study design 
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focused on maternal and infant factors identifiable at time of delivery, but given more than 
half of the overdoses happened greater than six months after delivery, important 
characteristics just prior to the overdose such as engagement in MOUD were not known. 
Fourth, ambulance trip overdose data were only available from 2013–2015, so it is possible 
overdoses that did not result in hospital visits were missed, resulting in an underestimation 
of the overdoses in 2012. Fifth, stratifying our analysis by OUD status likely limited our 
ability to fully detect associations. Despite these limitations, our analysis is strengthened by 
the ability to report population-level data in Massachusetts and utilize a novel linked public 
health dataset.
We identified that maternal diagnosis of OUD, prior non-fatal overdose, infant diagnosis of 
NAS, and high unscheduled health care utilization are associated with postpartum overdose. 
Engagement in methadone or buprenorphine treatment in the month prior to delivery was not 
sufficient to reduce the odds of postpartum overdose, suggesting that early screening, 
continuous access to health care, and tight linkage to postpartum care providers are essential 
for women to maintain treatment adherence. Finally, more than 50% of women with a 
postpartum overdose did not have prior evidence of OUD, suggesting that an additional 
focus on screening women for OUD at delivery and postpartum, with sustained postpartum 
maternal support, is critical to efforts to reduce pregnancy-associated morbidity and improve 
the health of families.
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Figure 1: 
Study Schema
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Figure 2: 
Adjusted Odds Ratios for Postpartum Opioid Overdose, Stratified by OUD Diagnosis 
(N=174,517)
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Table 1:
Maternal and Infant Characteristics by Postpartum Opioid Overdose (N=174,517)
OD event during 365 days 
following delivery (n= 
189)
No OD event during 365 days 
following delivery (n= 
174,328)
OD Rate per 10,000 live 
births
Characteristics n % n % Rate (95% CI)
Maternal Demographics
Maternal Age
 ≤ 25 years old 88 46.6% 34,662 19.9% 25.3 (20.0, 30.6)
 26–30 years old 61 32.3% 45,994 26.4% 13.2 (9.9, 16.6)
 ≥ 31 years old 40 21.2% 93,672 53.7% 4.3 (2.9, 5.6)
Maternal Race/Ethnicity
 White non-Hispanic 153 81.0% 111,031 63.7% 13.8 (11.6, 15.9)
 Other race/ethnicity 36 19.1% 63,297 36.3% 5.7 (3.8, 7.5)
Maternal Education
 High School or less 117 61.9% 47,295 27.1% 24.7 (20.2, 29.1)
 Some College or more 72 38.1% 127,033 72.9% 5.7 (4.4, 7.0)
Marital Status
 Married 35 18.5% 114,985 66.0% 3.0 (2.0, 4.1)
 Not Married 154 81.5% 59,343 34.0% 25.9 (21.8, 30.0)
Enrolled in MassHealth at Delivery
 Yes 173 91.5% 73,045 41.9% 23.6 (20.1, 27.1)
 No 16 8.5% 101,283 58.1% 1.6 (0.8, 2.4)
Pregnancy Variables
Breastfeeding at Discharge
 Yes 90 47.6% 145,117 83.2% 6.2 (4.9, 7.5)
 No 99 52.4% 29,211 16.8% 33.8 (27.1, 40.4)
Preterm or Low Birth Weight (% Yes)
 Yes 50 26.5% 16,707 9.6% 29.8 (21.6, 38.1)
 No 139 73.5% 157,621 90.4% 8.8 (7.3, 10.3)
Adequacy of Prenatal Care*
 Less than Adequate 80 42.3% 36,888 21.2% 21.6 (16.9, 26.4)
 Adequate 50 26.5% 72,899 41.8% 6.9 (5.0, 8.8)
 Intensive 59 31.2% 64,541 37.0% 9.1 (6.8, 11.5)
Method of Delivery
 Vaginal 120 63.5% 120,866 69.3% 9.9 (8.1, 11.7)
 C-Section 69 36.5% 53,462 30.7% 12.9 (9.8, 15.9)
NAS Diagnosis
 Yes 66 34.9% 1,892 1.1% 337.1 (255.8, 418.4)
 No 123 65.1% 172,436 98.9% 7.1 (5.9, 8.4)
Opioid Related Variables
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OD event during 365 days 
following delivery (n= 
189)
No OD event during 365 days 
following delivery (n= 
174,328)
OD Rate per 10,000 live 
births
Characteristics n % n % Rate (95% CI)
Enrolled in BSAS Program for Opioid 
Problem (12MB) (% Yes)
67 35.5% 1,233 0.7% 515.4 (392.0, 638.8)
Type of MOUD (12MB)
 Buprenorphine only 32 16.9% 1,210 0.7% 257.6 (158.4, 346.9)
 Methadone only 32 16.9% 1,071 0.6% 290.1 (189.6, 390.6)
 Mixed 14 7.4% 233 0.1% 566.8 (269.9, 863.7)
 None 111 58.7% 171,814 98.6% 6.5 (5.3, 7.7)
MOUD during month of delivery (% Yes) 56 29.6% 1,935 1.1% 281.3 (207.6, 354.9)
Non-fatal Opioid Overdose (12MB) (% Yes) 12 6.4% 67 0.04% 1519.0 (659.5, 2378.4)
OUD Diagnosis (Casemix or APCD) (12MB)
 Yes 88 46.6% 2,431 1.4% 349.3 (276.4, 422.3)
 No 101 53.4% 171,897 98.6% 5.9 (4.7, 7.0)
Opioid RX† Filled (3MB‡)
 Yes 14 7.4% 4,347 2.5% 32.1 (15.3, 48.9)
 No 175 92.6% 169,981 97.5% 10.3 (8.8, 11.8)
Healthcare Utilization
Any Emergency department visit (12MB‡
 Yes 116 61.4% 36,280 20.8% 31.9 (26.1, 37.7)
 No 73 38.6% 138,048 79.2% 5.3 (4.1, 6.5)
Any Hospital admission (12MB‡)
 Yes 51 27.0% 8,637 5.0% 58.7 (42.6. 74.8)
 No 138 73.0% 165,691 95.1% 8.3 (6.9, 9.7)
Any Observational Stay (12MB‡)
 Yes 24 12.7% 7,925 4.6% 30.2 (18.1, 42.3)
 No 165 87.3% 166,403 95.5% 9.9 (8.4, 11.4)
Any Inpatient or ED utilization (12MB‡)
 Yes 122 64.6% 43,711 25.1% 27.8 (22.9, 32.8)
 No 67 35.5% 130,617 74.9% 5.2 (3.9, 6.4)
High Utilization of ED (12MB‡)
 3 or more ED or OB triage visits 77 40.7% 9,292 5.3% 82.2 (66.8, 100.5)
 Less than three visits 112 59.3% 165,036 94.7% 6.8 (5.5, 8.0)
Mental Health Variables
Anxiety Diagnosis (12MB)
 Yes 69 36.5% 7,821 4.5% 87.5 (66.8, 108.1)
 No 120 63.5% 166,507 95.5% 7.2 (5.2, 8.5)
Depression Diagnosis (12MB)
 Yes 71 37.6% 9,646 5.5% 73.1 (56.1, 90.1)
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OD event during 365 days 
following delivery (n= 
189)
No OD event during 365 days 
following delivery (n= 
174,328)
OD Rate per 10,000 live 
births
Characteristics n % n % Rate (95% CI)
 No 118 62.4% 164,682 94.4% 7.2 (5.2, 8.5)
Incarceration and Homelessness Variables
Incarcerated in Prison or Jail (12MB)
 Yes 18 9.5% 359 0.2% 477.5 (256.9, 698.0)
 No 171 90.5% 173,969 99.9% 9.8 (8.3, 11.3)
Homelessness - shelter/hotel case file (12MB)
 Yes 15 7.9% 2,049 1.2% 72.7 (35.9, 109.5)
 No 174 92.1% 172,279 98.8% 10.1 (8.6, 11.6)
†
Excluding Buprenorphine, 3MB‡ = in the 3 months before delivery - exclusive, 12MB= in the 12 months before delivery - inclusive, 12MB‡ = in 
the 12 months before delivery - exclusive, SP=in study period (2011–2015)
APCD = All Payer Claims Database, BSAS = Bureau of Substance Addiction Services, Casemix = Hospital discharge data, DHCD = Department 
of Housing and Community Development, DPH = Department of Public Health, MOUD=Medication for Opioid Use Disorder NAS = Neonatal 
Abstinence Syndrome
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Table 2:
Comparison of Maternal and Infant Characteristics among Women with Postpartum Overdose by Evidence of 
Opioid Use Disorder (N=189)
Evidence of OUD in 12 
months before delivery, 
inclusive (n= 88)
No Evidence of OUD in 12 
months before delivery, 
inclusive (n= 101)
Characteristics n % n % p-value
Maternal Demographics
Maternal Age 0.200
 ≤ 25 years old 35 39.8% 53 52.5%
 26–30 years old 31 35.2% 30 29.7%
 ≥ 31 years old 22 25.0% 18 17.8%
Maternal Race/Ethnicity 0.001
 White non-Hispanic * * 73 72.3%
 Other race/ethnicity * * 28 27.7%
Maternal Education 0.024
 High School or less 62 70.5% 55 54.5%
 Some College or more 26 29.6% 46 45.5%
Marital Status 0.911
 Married 16 18.2% 19 18.8%
 Not Married 72 81.8% 82 81.2%
Enrolled in MassHealth at Delivery (% Yes) * * 11 10.9% 0.199
Pregnancy Variables
Breastfeeding at Discharge (% Yes) 28 31.8% 62 61.4% <0.001
Preterm or Low Birth Weight (% Yes) 25 28.4% 25 24.8% 0.570
Adequacy of Prenatal Care <0.001
 Less than Adequate 51 58.0% 29 28.7%
 Adequate 13 14.8% 37 36.6%
 Intensive 24 27.3% 35 34.7%
Method of Delivery 0.344
 Vaginal 59 67.1% 61 60.4%
 C-Section 29 33.0% 40 39.6%
NAS Diagnosis (% Yes) 56 63.6% * * <0.001
Opioid Related Variables
Enrolled in BSAS Program for Opioid Problem (12MB) (% 
Yes)
50 56.8% 17 16.8% <0.001
Any MOUD (12MB) (% Yes) 67 76.1% 11 10.9% <0.001
MOUD during month of delivery (% Yes) 50 56.8% * * <0.001
Non-fatal Opioid Overdose (12MB) (% Yes) 11 12.5% * * 0.001
Healthcare Utilization
Any Emergency department visit (12MB‡) (% Yes) 67 76.1% 49 48.5% <0.001
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Evidence of OUD in 12 
months before delivery, 
inclusive (n= 88)
No Evidence of OUD in 12 
months before delivery, 
inclusive (n= 101)
Characteristics n % n % p-value
Any Hospital admission (12MB‡) (% Yes) 38 43.2% 13 12.9% <0.001
Any Observational Stay (12MB‡) (% Yes) 19 21.6% * * 0.001
Any Inpatient or ED utilization (12MB‡) (% Yes) 70 79.6% 52 51.5% <0.001
ED Visits (12MB‡) (% Yes) 48 51.4% 29 28.7% <0.001
Mental Health Variables
Anxiety Diagnosis (12MB) (% Yes) 50 56.8% 19 18.8% <0.001
Depression Diagnosis (12MB) (% Yes) 50 56.8% 21 20.8% <0.001
Incarceration and Homelessness Variables
Incarcerated in Prison or Jail (12MB) (% Yes) 11 12.5% * * 0.193
DHCD shelter/hotel case file (12MB) (% Yes) 11 12.5% * * 0.030
*Values suppressed due to privacy restrictions. Any non-zero value < 11 is suppressed. If only one value is suppressed in a category, the next 
smallest value is also suppressed to prevent back calculation.
3MB‡ = in the 3 months before delivery - exclusive, 12MB= in the 12 months before delivery - inclusive, 12MB‡ = in the 12 months before 
delivery - exclusive, SP=in study period (2011–2015)
APCD = All Payer Claims Database, Casemix = Hospital discharge data, DHCD = Department of Housing and Community Development, 
MOUD=Medication for Opioid Use Disorder, NAS = Neonatal Abstinence Syndrome
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